Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Holmes

Pulmonary Disease Pollocksville, NC Medical Doctor

NPI 1780769232 CMS profile 1182658

137 Medical Ln, Pollocksville, NC 28573

Open in the dashboard

General payments

$10,905

497 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Holmes of Pollocksville, NC is reported in the CMS Open Payments database as having received $10,905 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,021 138
2024 General $2,005 94
2023 General $1,594 75
2022 General $1,146 59
2021 General $616 33
2020 General $1,363 20
2019 General $1,160 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Holmes
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jennifer Holmes were reported at $3,021. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jennifer Holmes Pulmonary Disease median Middle half National median
2019 $1,160 $377 $109–$1,340 $163
2020 $1,363 $230 $56–$907 $114
2021 $616 $269 $68–$1,072 $132
2022 $1,146 $390 $100–$1,457 $149
2023 $1,594 $419 $114–$1,659 $160
2024 $2,005 $476 $123–$1,818 $164
2025 $3,021 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,915 115 payments
  2. GlaxoSmithKline, LLC. $1,694 114 payments
  3. C. R. Bard, Inc. & Subsidiaries $1,054 2 payments
  4. Amgen Inc. $705 45 payments
  5. Genzyme Corporation $670 29 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $651 34 payments
  7. Regeneron Healthcare Solutions, Inc. $579 27 payments
  8. Insmed, Inc. $445 22 payments
  9. United Therapeutics Corporation $326 14 payments
  10. Genentech USA, Inc. $320 21 payments
  11. Other $1,545 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,725 491 payments
  2. Consulting Fee $1,050 1 payment
  3. Education $126 4 payments
  4. Travel and Lodging $4 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA $1,322 35 payments
  2. BREZTRI $1,197 34 payments
  3. TEZSPIRE Respiratory $987 19 payments
  4. AIRSUPRA $777 10 payments
  5. TRELEGY ELLIPTA $770 47 payments
  6. NUCALA $761 54 payments
  7. DUPIXENT $725 29 payments
  8. OFEV $414 23 payments
  9. TEZSPIRE Inflammation $414 31 payments
  10. Arikayce $360 18 payments
  11. Other $4,737 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

5,025

Median for Pulmonary Disease: 936

Drug cost

$2,480,376

Median for Pulmonary Disease: $487,987

Branded share of claims

65.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 633 $482,515
Ofev Nintedanib Esylate Brand 22 $343,825
Dupixent Pen Dupilumab Brand 73 $306,801
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 323 $257,282
Fasenra Benralizumab Brand 31 $201,760
Dupixent Syringe Dupilumab Brand 35 $147,990
Nucala Mepolizumab Brand 28 $130,149
Spiriva Respimat Tiotropium Bromide Brand 193 $123,583
Tezspire Tezepelumab-Ekko Brand 23 $104,901
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 95 $59,461

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 113 billing codes

Paid by Medicare

$924,991

Of which drugs: $685,778

Medicare patients

673

Average age 74

Services billed

46,924

394 women, 279 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 70%
Arthritis 55%
Ischemic heart disease 41%
Diabetes 38%
Heart failure 32%
Atrial fibrillation 28%
Chronic kidney disease 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tezepelumab-ekko, 1 mg J2356 Office 22 25,431 $361,034
Injection, mepolizumab, 1 mg J2182 Office 15 9,501 $226,065
Pcv20 vaccine im 90677 Office 11 11 $3,204
Vaccine for influenza for injection into muscle 90662 Office 14 15 $1,217
Injection, methylprednisolone acetate, 1 mg J1010 Office 32 1,320 $136
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 13 $45
Injection, ceftriaxone sodium, per 250 mg J0696 Office 29 118 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $251
  • Regeneron Healthcare Solutions, Inc. $221
  • SANOFI-AVENTIS U.S. LLC $57
$530 108 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $303
$303 31 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $122
  • Amgen Inc. $48
$170 23 25,431
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $150
$150 633 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $150
$150 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record